Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Increased mutant KRAS gene dosage drives pancreatic cancer progression: evidence for wild-type KRAS as a tumor suppressor?

Kent OA.

Hepatobiliary Surg Nutr. 2018 Oct;7(5):403-405. doi: 10.21037/hbsn.2018.07.03. No abstract available.

2.

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge.

Kent OA, Steenbergen C, Das S.

J Vis Exp. 2018 Jun 15;(136). doi: 10.3791/57845.

3.

Radical probing of spliceosome assembly.

Grewal CS, Kent OA, MacMillan AM.

Methods. 2017 Aug 1;125:16-24. doi: 10.1016/j.ymeth.2017.06.030. Epub 2017 Jun 29.

PMID:
28669867
4.

Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition.

Kent OA, Sandi MJ, Rottapel R.

Small GTPases. 2019 Nov;10(6):441-448. doi: 10.1080/21541248.2017.1337545. Epub 2017 Jul 11.

PMID:
28656876
5.

RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146.

Matsumoto Y, Larose J, Kent OA, Lim M, Changoor A, Zhang L, Storozhuk Y, Mao X, Grynpas MD, Cong F, Rottapel R.

J Clin Invest. 2017 Apr 3;127(4):1303-1315. doi: 10.1172/JCI90527. Epub 2017 Mar 13.

6.

Divergent Effects of miR-181 Family Members on Myocardial Function Through Protective Cytosolic and Detrimental Mitochondrial microRNA Targets.

Das S, Kohr M, Dunkerly-Eyring B, Lee DI, Bedja D, Kent OA, Leung AK, Henao-Mejia J, Flavell RA, Steenbergen C.

J Am Heart Assoc. 2017 Feb 27;6(3). pii: e004694. doi: 10.1161/JAHA.116.004694.

7.

An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.

Kent OA, Sandí MJ, Burston HE, Brown KR, Rottapel R.

Oncotarget. 2017 Jan 17;8(3):4484-4500. doi: 10.18632/oncotarget.13152.

8.

Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2.

Matsumoto Y, La Rose J, Kent OA, Wagner MJ, Narimatsu M, Levy AD, Omar MH, Tong J, Krieger JR, Riggs E, Storozhuk Y, Pasquale J, Ventura M, Yeganeh B, Post M, Moran MF, Grynpas MD, Wrana JL, Superti-Furga G, Koleske AJ, Pendergast AM, Rottapel R.

J Clin Invest. 2016 Dec 1;126(12):4482-4496. doi: 10.1172/JCI87802. Epub 2016 Oct 31.

9.

Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1.

Kent OA, Mendell JT, Rottapel R.

Mol Cancer Res. 2016 Mar;14(3):267-77. doi: 10.1158/1541-7786.MCR-15-0456. Epub 2016 Jan 8.

10.

Lessons from miR-143/145: the importance of cell-type localization of miRNAs.

Kent OA, McCall MN, Cornish TC, Halushka MK.

Nucleic Acids Res. 2014 Jul;42(12):7528-38. doi: 10.1093/nar/gku461. Epub 2014 May 29. Review.

11.

The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1.

Cullis J, Meiri D, Sandi MJ, Radulovich N, Kent OA, Medrano M, Mokady D, Normand J, Larose J, Marcotte R, Marshall CB, Ikura M, Ketela T, Moffat J, Neel BG, Gingras AC, Tsao MS, Rottapel R.

Cancer Cell. 2014 Feb 10;25(2):181-95. doi: 10.1016/j.ccr.2014.01.025.

12.

RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets.

Kent OA, Fox-Talbot K, Halushka MK.

Oncogene. 2013 May 16;32(20):2576-85. doi: 10.1038/onc.2012.266. Epub 2012 Jul 2.

PMID:
22751122
13.

Nuclear miRNA regulates the mitochondrial genome in the heart.

Das S, Ferlito M, Kent OA, Fox-Talbot K, Wang R, Liu D, Raghavachari N, Yang Y, Wheelan SJ, Murphy E, Steenbergen C.

Circ Res. 2012 Jun 8;110(12):1596-603. doi: 10.1161/CIRCRESAHA.112.267732. Epub 2012 Apr 19.

14.

MicroRNA profiling of diverse endothelial cell types.

McCall MN, Kent OA, Yu J, Fox-Talbot K, Zaiman AL, Halushka MK.

BMC Med Genomics. 2011 Nov 2;4:78. doi: 10.1186/1755-8794-4-78.

15.

Role of pri-miRNA tertiary structure in miR-17~92 miRNA biogenesis.

Chaulk SG, Thede GL, Kent OA, Xu Z, Gesner EM, Veldhoen RA, Khanna SK, Goping IS, MacMillan AM, Mendell JT, Young HS, Fahlman RP, Glover JN.

RNA Biol. 2011 Nov-Dec;8(6):1105-14. doi: 10.4161/rna.8.6.17410. Epub 2011 Nov 1.

PMID:
21955497
16.

Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice.

Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A.

Mol Cancer Ther. 2011 Aug;10(8):1470-80. doi: 10.1158/1535-7163.MCT-11-0152. Epub 2011 May 27.

17.

Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.

Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, Mendell JT.

Genes Dev. 2010 Dec 15;24(24):2754-9. doi: 10.1101/gad.1950610.

18.

Identifying targets of miR-143 using a SILAC-based proteomic approach.

Yang Y, Chaerkady R, Kandasamy K, Huang TC, Selvan LD, Dwivedi SB, Kent OA, Mendell JT, Pandey A.

Mol Biosyst. 2010 Oct;6(10):1873-82. doi: 10.1039/c004401f. Epub 2010 Jun 14.

19.

A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.

Kent OA, Mullendore M, Wentzel EA, López-Romero P, Tan AC, Alvarez H, West K, Ochs MF, Hidalgo M, Arking DE, Maitra A, Mendell JT.

Cancer Biol Ther. 2009 Nov;8(21):2013-24.

20.

Proteins specifically modified with a chemical nuclease as probes of RNA-protein interaction.

Kent OA, Macmillan AM.

Methods Mol Biol. 2008;488:191-200. doi: 10.1007/978-1-60327-475-3_13. No abstract available.

PMID:
18982292
21.

Functional integration of microRNAs into oncogenic and tumor suppressor pathways.

Lotterman CD, Kent OA, Mendell JT.

Cell Cycle. 2008 Aug 15;7(16):2493-9. Epub 2008 Aug 17.

22.

Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.

Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT.

Mol Cell. 2007 Jun 8;26(5):745-52. Epub 2007 May 31.

23.

A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Kent OA, Mendell JT.

Oncogene. 2006 Oct 9;25(46):6188-96. Review.

PMID:
17028598
24.

Crystal structure of a core spliceosomal protein interface.

Schellenberg MJ, Edwards RA, Ritchie DB, Kent OA, Golas MM, Stark H, Lührmann R, Glover JN, MacMillan AM.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1266-71. Epub 2006 Jan 23.

25.
26.

RNAi: running interference for the cell.

Kent OA, MacMillan AM.

Org Biomol Chem. 2004 Jul 21;2(14):1957-61. Epub 2004 Jun 28. Review.

PMID:
15254617
27.

Structuring of the 3' splice site by U2AF65.

Kent OA, Reayi A, Foong L, Chilibeck KA, MacMillan AM.

J Biol Chem. 2003 Dec 12;278(50):50572-7. Epub 2003 Sep 23.

28.

Early organization of pre-mRNA during spliceosome assembly.

Kent OA, MacMillan AM.

Nat Struct Biol. 2002 Aug;9(8):576-81.

PMID:
12091875

Supplemental Content

Support Center